Interventional cardiologist @MidAmericaHeart. Professor of Medicine, University of Missouri - Kansas City
Leawood, KS
Joined July 2016
- Tweets385
- Following134
- Followers373
- Likes2.4K
Acute Cardiovascular Responses to Amphetamine/Dextroamphetamine Salts (Adderall) in Adderall-Naïve Young Adults: A Randomized Clinical Trial - Mayo Clinic Proceedings mayoclinicproceedings.org/ar…
Understanding peripheral arterial disease in the current era - The Lancet thelancet.com/journals/lance…
Dmitri Baklanov MD, PhD retweeted
🚨 Applications for the 2026 #SCAIFellows Courses close October 9.
Join hundreds of future interventional cardiologists in Miami this December for hands-on learning, expert faculty instruction, networking, and scholarship support.
Apply for scholarship today ➡️ ow.ly/pj8o50ZOWQb
#InterventionalCardiology #CardioX #CardioEd
Dmitri Baklanov MD, PhD retweeted
SGLT2 inhibitors have transformed how we treat heart and kidney disease. Could they also change how we approach healthy aging?
In our first review in @opensourcecards, we explore their potential as geroprotectors: therapies that may influence the biology of aging and extend the years we live in good health.
Across 13 placebo-controlled trials involving 90,413 participants, SGLT inhibition reduced all-cause mortality by 12% relative to placebo (HR 0.88; 95% CI 0.83–0.94). These therapies also reduce heart failure hospitalizations and slow chronic kidney disease progression in the populations studied.
Preclinical and translational studies suggest effects on cellular recycling, mitochondrial function, inflammation, and cellular senescence—processes closely connected to aging.
SGLT2i deserve a prominent place in the healthy-aging research agenda. The next step is to test whether their benefits extend to preserving healthspan before disease develops.
Congratulations to my colleagues @BrettSperryMD and @jtsaxon for developing @opensourcecards truly an amazing innovation for our field for disseminating science.
opensourcecardiology.org/doi…
Dmitri Baklanov MD, PhD retweeted
A Foot Ulcer Is a Whole-Body Diagnosis: New 5698 Patient Cohort Puts DFU Survival Back in the Cancer Conversation — But There’s Hope #DiabeticFoot #ActAgainstAmputation #ToeandFlow diabeticfootonline.com/2026/…
Dmitri Baklanov MD, PhD retweeted
As imagers, our time spent in the reading room discussing difficult cases and reviewing images with colleagues does not generate any more RVUs, but is some of the most collegial, enjoyable, and human interactions we have left.
Resist the EPIC chat, and come down to the reading room to talk to us!
@LisaRosenbaum17 delivering a thought-provoking keynote speech at #ASNC2026 on “Preserving the sanctity of medicine in changing times”
@MyASNC @NEJM
Dmitri Baklanov MD, PhD retweeted
Today's the 49th anniversary of Andreas Gruentzig doing the 1st coronary angioplasty. Watch this extended version of the story, told by those who were there: Adolph Bachman (1st patient) Bernhard Meier (his doctor) & Maria Schlumpf (Gruentzig's assistant). Next year's the 50th: surprises coming! #AngioHistory
Dmitri Baklanov MD, PhD retweeted
Tomorrow's the 49th anniversary of Andreas Gruentzig doing the 1st coronary angioplasty. Watch this extended version of the story, told by those who were there: Adolph Bachmann (1st patient) Bernhard Meier (his doctor) & Maria Schlumpf (Gruentzig's assistant). Next year's the 50th: surprises coming! #AngioHistory
Dmitri Baklanov MD, PhD retweeted
The Saint Luke's Cardiovascular Structural Intervention Fellowship program application window is now open. Train with a nationally recognized cardiovascular team. Learn more: bit.ly/4hU1NFw
Dmitri Baklanov MD, PhD retweeted
Saint Luke’s Cardiovascular Disease Fellowship applications are open!
@UMKC and Saint Luke's @MidAmericaHeart offer:
✴️ 3-yr CV fellowship
✴️ 2-yr T32 track
✴️ Advanced HF
✴️ EP
✴️ Interventional
✴️ Structural
✴️ CV Imaging
✴️ Prevention
Learn more: bit.ly/4yb6Mqg
Dmitri Baklanov MD, PhD retweeted
1/
Every interventional cardiologist has been trained that radiation dose is their responsibility: fluoro time, frame rates, collimation. Nobody asks how old the machine is. We asked. Median age: 17 years. 🧵
Dmitri Baklanov MD, PhD retweeted
First-in-class, novel-mechanism agents tested in Phase 3 CV outcomes trials have <20% success rate
It is very challenging to incrementally/meaningfully improve CV outcomes
Yet, tragic when there are proven therapies, but not implemented, and preventable events allowed to occur
Dmitri Baklanov MD, PhD retweeted
🚨 Just Announced! Be among the first to see landmark research with the potential to change clinical practice and shape the future of cardiovascular care.
🔬 New Evidence💡 Fresh Insights ❤️ Clinical Impact
Explore the newly revealed late-breaking sessions and register today for #TCT2026! ow.ly/jIIp50ZFPTF
#CardioX #CardioTwitter #CardioEd #CardioResearch @BurkhoffMd @djc795 @ColletCarlos @georgedangas @jgranadacrf @mbmcentegart @Drroxmehran @sahilparikhmd @PopmaJeffrey @triciarawh @mirvatalasnag @TCTConference @TCTMD
Dmitri Baklanov MD, PhD retweeted
Don't ignore leg pain! Talk to your doctor to see if vascular testing should be done to evaluate for #PAD! @mnyoung1 @MayoClinicCV @DHCVFellowship @ACCinTouch @PVDCouncil
What is one thing vascular medicine experts wish more people knew?
Don't ignore your symptoms.
PAD is often underdiagnosed, but early diagnosis and treatment can help prevent serious complications.
Watch the video to hear why awareness matters.
#VascularMedicine #PAD #SVM
@stanhenkin
Dmitri Baklanov MD, PhD retweeted
Most journals ask researchers to adapt to the publishing system.
We built the system around researchers.
$0 to publish original research.
100% open access.
Authors retain copyright.
Reviewers are recognized for their work.
Physicians make the scientific decisions.
That’s our permanent commitment to science.
Join the movement:
opensourcecardiology.org
Dmitri Baklanov MD, PhD retweeted
Refining the Role of Beta-Blockers in Cardiovascular Medicine - ScienceDirect led by my colleague @BrettSperryMD sciencedirect.com/science/ar…
Dmitri Baklanov MD, PhD retweeted
The newest SRTR report confirms what our team sees every day: the heart transplant program at @MidAmericaHeart is delivering exceptional outcomes while also getting patients transplanted quickly!
In summary, we have 100% 1 month and 1 year survival this cycle with the best risk-adjusted survival in the country (76% better than expected) and our offer acceptance is 2x the national average.
Rapid treatment for our waitlisted patients with excellent outcomes!
Lucky to be working with this outstanding team every day @AndrewJSauer @MichaelNassifMD @tjfendler @MagalskiAnthony @meverley @smccarneyMD @cardiackid68
